Fortress Biotech Subsidiary Sells Rare Disease Priority Voucher for $205M

Cyprium Therapeutics, a majority-owned subsidiary of Fortress Biotech, closes sale of rare pediatric disease priority review voucher.

Mar. 31, 2026 at 3:33am

Got story updates? Submit your updates here. ›

A photorealistic studio still life of a polished glass vial filled with a golden liquid, symbolizing the rare disease treatment developed by Cyprium Therapeutics. The vial is elegantly arranged on a clean, monochromatic background using dramatic lighting and shadows to convey the abstract corporate strategy behind the $205 million voucher sale.The $205 million sale of Cyprium's rare disease priority review voucher represents a transformative financial milestone for the Fortress Biotech subsidiary.Today in Miami

Fortress Biotech, Inc. and its majority-owned subsidiary, Cyprium Therapeutics, Inc., announced the closing of the sale of Cyprium's Rare Pediatric Disease Priority Review Voucher for gross proceeds of $205 million. The sale is a transformational corporate transaction that will enhance Fortress' financial flexibility to invest in business development and its robust portfolio.

Why it matters

The sale of the priority review voucher provides a significant financial boost for Fortress Biotech and its subsidiary Cyprium Therapeutics. The funds will allow Fortress to further invest in advancing its diverse portfolio of commercial and clinical-stage assets, including recent FDA approvals for three of its products.

The details

The priority review voucher was issued upon FDA approval of Cyprium's ZYCUBO (copper histidinate) for the treatment of Menkes disease in pediatric patients in January 2026. Pursuant to a prior agreement, the voucher was immediately transferred to Cyprium, which has now sold it for $205 million. Cyprium remains eligible for tiered royalties and milestone payments related to ZYCUBO from its partner Sentynl Therapeutics.

  • The priority review voucher was issued on January 12, 2026 upon FDA approval of ZYCUBO.
  • Cyprium closed the sale of the voucher on March 30, 2026.

The players

Fortress Biotech, Inc.

An innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders.

Cyprium Therapeutics, Inc.

A majority-owned subsidiary of Fortress Biotech that is focused on developing novel therapies for the treatment of Menkes disease and related copper metabolism disorders.

Sentynl Therapeutics, Inc.

The company that assumed full responsibility for the development and commercialization of ZYCUBO (copper histidinate) from Cyprium in 2023.

Got photos? Submit your photos here. ›

What they’re saying

“The sale of the PRV by Cyprium is a transformational corporate transaction for both Cyprium and Fortress. As the majority shareholder of Cyprium, Fortress expects to receive over $100 million in proceeds from the transaction, which will enhance our financial flexibility to invest in business development and the continued advancement of our robust portfolio.”

— Lindsay A. Rosenwald, Chairman, President and Chief Executive Officer of Fortress Biotech and Chairman of Cyprium Therapeutics

What’s next

Cyprium remains eligible to receive tiered royalties on net sales of ZYCUBO and up to approximately $128 million in aggregate sales milestones from Sentynl Therapeutics.

The takeaway

The sale of the priority review voucher provides a significant financial boost for Fortress Biotech and its subsidiary Cyprium Therapeutics, allowing the company to further invest in advancing its diverse portfolio of commercial and clinical-stage assets, including recent FDA approvals for three of its products.